Alzheimer’s Association Welcomes U.S. FDA Approval of Lecanemab

Association Renews Urgent Call for CMS to Cover FDA-Approved Alzheimer’s Treatments CHICAGO, January 6, 2023 — The Alzheimer’s Association enthusiastically welcomes today’s U.S. Food and Drug Administration (FDA) action to grant the accelerated approval of Leqembi™ (lecanemab) (Eisai/Biogen) for the treatment of patients in mild cognitive impairment (MCI) or mild dementia stage of Alzheimer’s disease and with confirmation …

Read More

Early Signs and Symptoms of Alzheimer’s

Memory loss that disrupts daily life may be a symptom of Alzheimer’s or other dementia. Alzheimer’s is a brain disease that causes a slow decline in memory, thinking and reasoning skills. There are 10 warning signs and symptoms. If you notice any of them, don’t ignore them. Schedule an appointment with your doctor. Get checked. …

Read More